{"authors": ["Gina Kolata"], "date_download": "2022-10-25 23:23:08", "date_modify": "2022-10-25 23:23:08", "date_publish": "2020-06-29 21:47:58", "description": "Federal health officials and Gilead Sciences have settled on priority distribution to Americans — and nonnegotiable pricing.", "filename": "2020_06_29_health_coronavirus-remdesivir-gilead_1666740188.html", "image_url": "https://static01.nyt.com/images/2020/06/29/science/29VIRUS-REMDESIVIR1/29VIRUS-REMDESIVIR1-facebookJumbo.jpg?year=2020&h=550&w=1050&s=c82ff07d9f4846a71c65eb7f0a1fe6841f98a7e02cc59c42fcd3a3133e92b8aa&k=ZQJBKqZ0VN", "language": "en", "localpath": "/Users/matthewwhite/news-please-repo//data/2022/10/25/nytimes.com/2020_06_29_health_coronavirus-remdesivir-gilead_1666740188.html", "title": "Remdesivir, the First Coronavirus Drug, Gets a Price Tag", "title_page": "Remdesivir, the First Coronavirus Drug, Gets a Price Tag - The New York Times", "title_rss": "NULL", "source_domain": "nytimes.com", "maintext": "Remdesivir, the first drug shown to be effective against the coronavirus, will be distributed under an unusual agreement with the federal government that establishes nonnegotiable prices and prioritizes American patients, health officials announced on Monday.\nThe arrangement may serve as a template for distribution of new treatments and vaccines as the pandemic swells, said Ernst Berndt, a retired health economist at the Massachusetts Institute of Technology Sloan School of Management.\nRemdesivir will be sold for $520 per vial, or $3,120 per treatment course, to hospitals for treatment of patients with private insurance, according to the Department of Health and Human Services and Gilead Sciences, the drug’s manufacturer.\nThe price will be set at $390 per vial, or $2,340 per treatment course, for patients on government-sponsored insurance and for those in other countries with national health care systems.", "url": "https://www.nytimes.com/2020/06/29/health/coronavirus-remdesivir-gilead.html"}